The 8p11 myeloproliferative syndrome (EMS), also referred to as stem cell leukemia/lymphoma, is a chronic myeloproliferative disorder that rapidly progresses into acute leukemia. Molecularly, EMS is characterized by fusion of various partner genes to the 
Introduction
The 8p11 myeloproliferative syndrome (EMS), also known as stem cell leukemia/lymphoma, is a myeloproliferative disorder (MPD) that WHO recently classified as belonging to the group of myeloid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. 1 Clinically, EMS is characterized by leukocytosis, eosinophilia, splenomegaly, and a short chronic phase that rapidly progresses into aggressive acute myeloid (AML) or lymphoblastic (ALL) leukemia. A prominent feature of the disease is an increased incidence of T-cell lymphomas, seen in 30% of the cases, suggesting that the target cell of transformation is a multipotent progenitor cell. 2 Although several FGFR1 inhibitors have been tested with promising effects in vitro, [3] [4] [5] the only cure for this disease at present is allogeneic bone-marrow (BM) transplantation.
At the molecular level EMS is characterized by various translocations fusing at least eight different 5' partner genes to the 3' part of the FGFR1 gene that encodes the tyrosine kinase domain. 6 In most of these fusion proteins, the amino terminal regions contain structural properties that allow them to dimerize or oligomerize, resulting in constitutive activation of FGFR1. 7 A limited number of studies in murine cells have addressed how FGFR1 fusion oncogenes elicit their transforming activities, mainly focusing on the two most common fusion gene variants ZMYM2/FGFR1 (previously known as ZNF198/FGFR1) and BCR/FGFR1. Expression of ZMYM2/FGFR1 in IL-3 dependent murine Ba/F3 cells resulted in growth-factor independent growth in which signal transducer and activator of transcription (STAT) 1, 2, 3, 4, 5, and 6 become constitutively tyrosine phoshorylated. 8, 9 Mice receiving transplants with ZMYM2/FGFR1-transduced mouse BM cells develop a condition that resemble EMS with MPD and T-cell lymphoma. 10 Moreover, mice that receive BCR/FGFR1-
transduced BM cell transplants develop a rapid fatal chronic myeloid leukemia (CML)-like
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From disease. 10 Although these studies in murine models have provided valuable pathogenetic insights into the different FGFR1 fusion genes, the functional consequences of their expression in primary human cells have not been addressed. In fact, the introduction of leukemia-associated fusion genes in primary human cells, followed by transplantation into immuno-deficient mice has, so far, been successful in reproducing the corresponding human disease only for the three fusion genes MLL/AF9(MLLT3), MLL/ENL(MLLT1), and
TEL(ETV6)/JAK2.

11-14
Herein, we demonstrate that retroviral expression of ZMYM2/FGFR1 or BCR/FGFR1
in human CD34 + hematopoietic cells induces an increased cellular proliferation and erythropoietin (EPO) -independent differentiation towards the erythroid lineage in vitro. In immuno-deficient mice, both fusion oncogenes induce an MPD-like disorder, accompanied by bone marrow fibrosis and blast accumulation, consistent with features observed in EMS patients. 15, 16 For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From
Materials and methods
Isolation, transduction, and sorting of cord blood CD34 + cells
The collection of cord blood (CB) was approved by the Lund University ethics committee and performed after informed consent in accordance with the Declaration of Helsinki. Samples from different donors were pooled, mononuclear cells were isolated by centrifugation over
Lymphoprep (Axis-Shield PoC A/S, Oslo, Norway), and the CD34 + cells were enriched by the use of MACS separation columns and isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of the CD34 + cells was routinely higher than 95% as assessed by flow cytometry.
The retroviral vectors MSCV-IRES-GFP (MIG), MIG-BCR/FGFR1, MIG
ZMYM2/FGFR1, MIG-BCR/ABL1, MIG-BCR/FGFR1 Y653/654F, MIG-ZMYM2/FGFR1
Y653/654F, and the lentiviral vectors short-hairpin RNA (shRNA) scramble and anti-STAT5
were used in this study. For origins, modifications, and production of these vectors, see μ g/mL streptomycin, 5U/mL EPO, 25 ng/mL SCF, 50 ng/mL granulocyte-macrophage colony-stimulating factor, and 25 ng/mL IL-3. After two weeks in culture, colonies were counted and replated at a dilution of 1:100. Two weeks later the secondary colonies were counted.
Cytospin preparations, flow cytometric analysis, and western blot analysis
Cells grown in suspension culture were collected at day 7 and 14. For morphological examination, cytospin slides were prepared by applying 1 x 10 4 cells onto glass slides followed by May-Grünwald and Giemsa staining. Cells harvested at the same time points
were stained with allophycocyanin-(APC) or phycoerythrin-(PE) conjugated antibodies against CD34, CD13, CD71, or CD235a (glycophorin A; GPA) (BD Immunocytometry Systems, Mountain View, CA) and analyzed by flow cytometry using a FACSCalibur or 18, 19 After irradiation, the mice were given antibiotics (ciprofloxacin) and powder food. At 6 and 9 or 12 weeks after injection of human cells, BM was collected from femur and cells were double stained with APC-conjugated anti CD45 and PE-conjugated anti-CD33/CD15, -CD34, or -CD235a (BD) antibodies, followed by flow cytometric analyses as described. 20 The mice were sacrificed at 9 to 12 weeks after injection of human cells, or earlier if found moribund. Spleen and femur (from leg not subjected to
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From BM-injection or -aspiration) were collected in 4% formalin, embedded in paraffin, and sectioned. Slides were stained for reticulin, with hematoxylin and eosin (HE), or immunostained with antibodies against CD3, CD4, CD15, CD20, CD34, CD45, CD68, CD79a, CD117, CD235a, and myeloperoxidase (MPO) (Dako, Glostrup, Denmark).
Antibodies used for immunostaining were controlled for cross-reactions with murine cells on BM sections from non-transplanted NOD/SCID control mice ( Figure S5 ). BM sections were also examined using Fluorescence in-situ hybridization (FISH) analysis as described in the Supplementary material. Figure S1A ). Successful expression of fusion proteins was confirmed by western blot analyses ( Figure S1B ). Figure 1C) . 17, 21, 22 To investigate if the FGFR1 tyrosine kinase activity was required for the increased proliferation and erythroid differentiation, we constructed variants previously shown to abolish kinase activity. ( Figure 2D ; Table S1 ). Gene ontology analysis of these 77 genes revealed that 'signal transducer activity' was the main top-ranked category (25 genes, Ease score 3.08 x 10 -4 ).
Notably, as many as 11 of the 77 genes (14%) were involved in the JAK-STAT signaling
pathway, including CISH, LEPR, LIF, OSM, PIM1, SOCS1-3, SOS1
, and the interleukin receptors IL2RB and IL7R. In parallel, 74 genes were found to be commonly downregulated by ZMYM2/FGFR1, BCR/FGFR1, and BCR/ABL1 when compared to MIG ( Figure 2E ; Table   S2 ). Although many genes were commonly regulated in the fusion gene-expressing cells, the individual fusion genes still displayed distinct gene-expression profiles with ZMYM2/FGFR1
and BCR/FGFR1 being more similar than BCR/ABL1 using multiclass SAM analysis ( Figure   S3B ).
Silencing of STAT5 with shRNA results in decreased proliferation of cells expressing
BCR/FGFR1, ZMYM2/FGFR1, or BCR/ABL1
We have previously demonstrated that BCR/ABL1-induced cell proliferation and erythroid differentiation in human CD34 + CB cells is partially STAT5 dependent. 17 In this study, gene (Table S3 and 
, human granulocytopoiesis displayed a left-shifted maturation pattern with marked expansion of myeloid cells at all stages of maturation, including eosinophilia, which is in agreement with findings described in the chronic phase of human EMS 7 ( Figure 4D ).
Interestingly, three of the BCR/FGFR1 animals displayed an accumulation of human blasts in the BM ( Figure 4D ). In two of the three animals, the blasts stained strongly positive for CD235a, suggesting the emergence of an acute erythroleukemia in these mice ( Figure 4D ). In one of these animals, the CD235a + blasts co-expressed CD117 indicating a more immature phenotype (data not shown). In the third mouse, the blast refrained staining with all antibodies used (CD3, CD4, CD15, CD20, CD34, CD45, CD68, CD79a, CD117, CD235a, and MPO)
suggesting an immature and primitive origin of these blasts (data not shown). These blasts stained positive for CD235a and CD117 ( Figure S8 and data not shown). None
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From of the NSG MIG control mice died due to disease during the study. There were no signs of lymphoid disease in any of the mice, irrespectively of the fusion gene used.
Given the close similarities in BM morphology between the BCR/FGFR1 and ZMYM2/FGFR1 mice and patients with EMS described in the literature, 24 we re-examined a BM biopsy taken from an EMS patient in which we originally isolated the BCR/FGFR1 fusion gene (Figure 7) . 16, 25 At the stage when the EMS had progressed into acute leukemia, the reticulin stained section revealed a pronounced increase of reticulin. Furthermore, HE staining revealed eosinophilia and infiltration of blasts that on immunohistochemical staining
were negative for all antibodies tested (CD3, CD4, CD8, CD15, CD20, CD34, CD45, CD68, CD79a, CD117, CD235, MPO, and TdT). This suggests an immature but otherwise 
Discussion
To study aberrant tyrosine kinases underlying human MPD, investigators have long been entirely dependent on leukemic cell lines and murine assays. Although these functional studies have contributed significantly to our knowledge regarding disease mechanisms in human MPD, there are noticeable limitations in both systems as cell lines typically acquire additional genetic aberrations for continuous growth in vitro, and tumorigenesis may differ substantially in man and mouse. 14, 26, 27 In this study we assessed the consequences of ectopic observed in CML patients has been difficult to achieve. [28] [29] [30] Moreover, the relatively rare occurrence of human EMS, and the fact that EMS in many cases is diagnosed in the late AML or ALL stage of the disease, severely limit similar types of studies.
Upon retroviral expression of ZMYM2/FGFR1 or BCR/FGFR1 in normal human
CD34 + CB cells we found an FGFR1 kinase dependent increased proliferation capacity and We have previously demonstrated that BCR/ABL1-induced erythroid differentiation and proliferation in human CD34 + CB cells is STAT5-dependent, 17 and it could be speculated that the FGFR1 fusion genes also mediate their effect through a similar mechanism.
EPO-independent erythroid differentiation in vitro, which is similar to BCR/ABL1-induced
Unexpectedly, the level of STAT5 phosphorylation was markedly lower in ZMYM2/FGFR1-expressing cells compared to BCR/FGFR1 and BCR/ABL1. Despite the differences in STAT5
phosphorylation, global gene-expression profiling revealed that all three fusion genes upregulated several genes involved in the JAK-STAT signaling pathway as well as other sets of genes, indicating that these fusion proteins share similar molecular programs. Using lentiviral STAT5 shRNA constructs, we were able to demonstrate a significant effect on the 
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Although the disease in mice much resembles human EMS, three distinct differences between the established model and human EMS are notable. First, patients with EMS often display a bilinear disease involving both the myeloid and the T-lymphoid lineage. We here failed to demonstrate a significant involvement of the human T-cell lineage in the immunodeficient mice. However, this may be explained by the inability of adult mice of both the NOD/SCID and the NSG strains to support T-lymphopoiesis after receiving transplants with human cells, possibly due to improper thymus development in these mice. 19, 35 Moreover, while T-cell involvement has been primarily reported in patients expressing ZMYM2/FGFR1, to our knowledge no EMS patient harboring a BCR/FGFR1 fusion gene has been reported to suffer from T-cell lymphoma/leukemia. 15, 16, [36] [37] [38] [39] [40] [41] [42] [43] Secondly, the accumulation of macrophages and mast cells in the BM of both BCR/FGFR1 and ZMYM2/FGFR1 mice may seem unexpected. However, when reviewing published cases with EMS, presence of mast cells in the BM and systemic mastocytosis have been reported in two cases. 44, 45 Upon re-examination of our previously described patient with EMS harboring a BCR/FGFR1 fusion gene, 16, 25 numerous mast cells and macrophages were found in the BM, although no prominent foci-like formations, as seen in the animal model, were observed. It is also interesting to note that mast cells often are enriched in eosinophilic myeloproliferative neoplasms caused by the closely related fusion genes involving PDGFRA/B. 46 Thirdly, in 5 of 6 animals with blast accumulation, the blasts displayed an erythroid phenotype. This is consistent with our in-vitro studies that demonstrated a strong erythroid potential of BCR/FGFR1-and ZMYM2/FGFR1-expressing cells. So far, FGFR1 fusion genes have not been associated with erythroleukemia, but we note with interest that two EMS patients were diagnosed with polycythemia vera, and one additional case developed erythroid BM hyperplasia. [47] [48] [49] In analogy with CML that may transform into an acute erythroleukemia, 50 we further speculate that kinase activating mutations of FGFR1 may be found in a fraction of acute erythroleukemia, representing an acute phase of an undiagnosed EMS chronic phase.
Global gene-expression analysis strongly indicated that both BCR/FGFR1 and ZMYM2/FGFR1 activates the JAK-STAT pathway, and the myelofibrosis seen in BCR/FGFR1 mice and ZMYM2/FGFR1 mice is similar to a recently described study in which human primary hematopoietic cells expressing the TEL/JAK2 fusion gene were transplanted into NOD/SCID mice. 12 Both our studies found atypical megakaryocytes of murine origin, suggesting that expression of a fusion oncogene such as BCR/FGFR1 or TEL/JAK2 in human cells can have cell non-autonomous effects on the mouse megakaryocytic lineage, perhaps contributing to fibrosis. In accordance with our in-vivo findings, fibrosis in the BM has been reported in three described EMS cases verified to harbor the BCR/FGFR1 fusion gene. 15, 16 In conclusion, we demonstrate that Normal BM 40x HE
